SG10202110563YA - Ganaxolone for use in treating genetic epileptic disoders - Google Patents
Ganaxolone for use in treating genetic epileptic disodersInfo
- Publication number
- SG10202110563YA SG10202110563YA SG10202110563YA SG10202110563YA SG10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA
- Authority
- SG
- Singapore
- Prior art keywords
- disoders
- ganaxolone
- treating genetic
- epileptic
- genetic epileptic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762584403P | 2017-11-10 | 2017-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202110563YA true SG10202110563YA (en) | 2021-11-29 |
Family
ID=66438123
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202110563YA SG10202110563YA (en) | 2017-11-10 | 2018-11-09 | Ganaxolone for use in treating genetic epileptic disoders |
SG11202004329TA SG11202004329TA (en) | 2017-11-10 | 2018-11-09 | Ganaxolone for use in treating genetic epileptic disoders |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202004329TA SG11202004329TA (en) | 2017-11-10 | 2018-11-09 | Ganaxolone for use in treating genetic epileptic disoders |
Country Status (10)
Country | Link |
---|---|
US (2) | US20190160078A1 (ja) |
EP (1) | EP3706755A4 (ja) |
JP (2) | JP7312169B2 (ja) |
KR (1) | KR20200085837A (ja) |
CN (1) | CN111565724A (ja) |
AU (1) | AU2018364659A1 (ja) |
CA (1) | CA3079259A1 (ja) |
EA (1) | EA202091144A1 (ja) |
SG (2) | SG10202110563YA (ja) |
WO (1) | WO2019094724A1 (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6205362B2 (ja) | 2011-09-08 | 2017-09-27 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
BR112014018110B1 (pt) | 2012-01-23 | 2022-06-07 | Sage Therapeutics, Inc | Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina |
ES2699445T3 (es) | 2013-03-13 | 2019-02-11 | Sage Therapeutics Inc | Esteroides neuroactivos y métodos de utilización de los mismos |
WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
CN108440633B (zh) | 2013-04-17 | 2021-07-13 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
ES2807264T3 (es) | 2013-04-17 | 2021-02-22 | Sage Therapeutics Inc | Esteroides neuroactivos 19-nor para métodos de tratamiento |
HUE053900T2 (hu) | 2013-07-19 | 2021-07-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, kompozíciók, és azok alkalmazásai |
BR112016003862B1 (pt) | 2013-08-23 | 2022-09-06 | Sage Therapeutics, Inc | Compostos esteroides neuroativos, suas composições e seus usos |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
EP3157528B1 (en) | 2014-06-18 | 2023-09-13 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
SG10202009859YA (en) | 2014-10-16 | 2020-11-27 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
EP3206493B1 (en) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
ME03749B (me) | 2014-11-27 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a |
RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
WO2016134301A2 (en) | 2015-02-20 | 2016-08-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
PE20180482A1 (es) | 2015-07-06 | 2018-03-07 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos |
MA55097A (fr) | 2015-07-06 | 2022-01-05 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
EP3426257A4 (en) | 2016-03-08 | 2019-11-13 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF |
LT3436022T (lt) | 2016-04-01 | 2022-06-27 | Sage Therapeutics, Inc. | Oksisteroliai ir jų panaudojimo būdai |
US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
RS62222B1 (sr) | 2016-07-07 | 2021-09-30 | Sage Therapeutics Inc | 24-hidroksisteroli supstituisani na poziciji 11 za upotrebu u lečenju stanja povezanih sa nmda |
DK3481845T3 (da) | 2016-07-11 | 2023-11-27 | Sage Therapeutics Inc | C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder |
US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
ES2952106T3 (es) | 2016-10-18 | 2023-10-27 | Sage Therapeutics Inc | Oxisteroles y procedimientos de utilización de los mismos |
EP3529256B1 (en) | 2016-10-18 | 2023-08-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
AU2019397565A1 (en) * | 2018-12-14 | 2021-07-08 | Praxis Precision Medicines, Inc. | Methods for the treatment of depression |
CN113272315B (zh) * | 2018-12-26 | 2023-08-08 | 张家口华健致远生物科技有限公司 | 一类类固醇化合物及其用途 |
JOP20210293A1 (ar) | 2019-05-31 | 2023-01-30 | Sage Therapeutics Inc | ستيرويدات ذات فعالية عصبية وتركيبات منها |
BR112022000429A2 (pt) | 2019-07-11 | 2022-03-29 | Praxis Prec Medicines Inc | Formulações de moduladores do canal de cálcio tipo t e métodos de uso dos mesmos |
WO2021067702A1 (en) * | 2019-10-02 | 2021-04-08 | Praxis Precision Medicines, Inc. | Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists |
KR20220134529A (ko) | 2019-12-06 | 2022-10-05 | 마리누스 파마슈티컬스 인코포레이티드 | 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론 |
CN115776894A (zh) * | 2020-04-29 | 2023-03-10 | 普拉西斯精密医药公司 | T型钙通道调节剂的使用方法 |
WO2022125408A1 (en) * | 2020-12-07 | 2022-06-16 | Marinus Pharmaceuticals, Inc | Use of ganaxolone in treating an epilepsy disorder |
WO2023060067A1 (en) * | 2021-10-04 | 2023-04-13 | Marinus Pharmaceuticals, Inc. | Amorphous solid dispersion ganaxolone formulation |
WO2023060024A1 (en) * | 2021-10-04 | 2023-04-13 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders |
US20230321116A1 (en) * | 2022-02-16 | 2023-10-12 | Lipocine Inc. | 3Alpha-OH-5Beta-Pregnan-20-One Compositions and Methods for Treating Central Nervous System Disorders |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5556847A (en) * | 1994-10-27 | 1996-09-17 | Duquesne University Of The Holy Ghost | Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors |
US5888996A (en) * | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
BR112014018110B1 (pt) * | 2012-01-23 | 2022-06-07 | Sage Therapeutics, Inc | Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina |
EP2887944B1 (en) * | 2012-08-21 | 2021-10-06 | Sage Therapeutics, Inc. | Allopregnanolone for treating refractory status epilepticus |
US9629853B2 (en) * | 2014-05-21 | 2017-04-25 | Wisconsin Alumni Research Foundation | Uses of ganaxolone |
EP3253418A1 (en) * | 2015-02-06 | 2017-12-13 | Marinus Pharmaceuticals, Inc. | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders |
CA3001722A1 (en) * | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
EP3426257A4 (en) * | 2016-03-08 | 2019-11-13 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF |
KR20230050474A (ko) * | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
AU2018255327A1 (en) * | 2017-04-18 | 2019-11-07 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
-
2018
- 2018-11-09 WO PCT/US2018/060037 patent/WO2019094724A1/en unknown
- 2018-11-09 EP EP18876989.7A patent/EP3706755A4/en active Pending
- 2018-11-09 KR KR1020207016409A patent/KR20200085837A/ko not_active Application Discontinuation
- 2018-11-09 SG SG10202110563YA patent/SG10202110563YA/en unknown
- 2018-11-09 CA CA3079259A patent/CA3079259A1/en active Pending
- 2018-11-09 SG SG11202004329TA patent/SG11202004329TA/en unknown
- 2018-11-09 CN CN201880085880.3A patent/CN111565724A/zh active Pending
- 2018-11-09 US US16/185,677 patent/US20190160078A1/en not_active Abandoned
- 2018-11-09 EA EA202091144A patent/EA202091144A1/ru unknown
- 2018-11-09 JP JP2020526304A patent/JP7312169B2/ja active Active
- 2018-11-09 AU AU2018364659A patent/AU2018364659A1/en active Pending
-
2022
- 2022-03-24 US US17/703,331 patent/US20220249515A1/en not_active Abandoned
-
2023
- 2023-07-07 JP JP2023112339A patent/JP2023153783A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20200085837A (ko) | 2020-07-15 |
SG11202004329TA (en) | 2020-06-29 |
US20220249515A1 (en) | 2022-08-11 |
JP2023153783A (ja) | 2023-10-18 |
EP3706755A1 (en) | 2020-09-16 |
CA3079259A1 (en) | 2019-05-16 |
EA202091144A1 (ru) | 2020-09-16 |
US20190160078A1 (en) | 2019-05-30 |
WO2019094724A1 (en) | 2019-05-16 |
EP3706755A4 (en) | 2021-11-10 |
WO2019094724A8 (en) | 2022-10-06 |
JP2021502403A (ja) | 2021-01-28 |
JP7312169B2 (ja) | 2023-07-20 |
AU2018364659A1 (en) | 2020-05-28 |
CN111565724A (zh) | 2020-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10202110563YA (en) | Ganaxolone for use in treating genetic epileptic disoders | |
EP3364869C0 (en) | SYSTEM FOR THE PROCESSING OF A NEURAL PLACE IN A BODY | |
HK1245287A1 (zh) | IL13RAα2結合劑和其在癌症治療中的用途 | |
IL272596A (en) | Pridopidine for use in the treatment of ALS | |
SI3307296T1 (sl) | TIMP2 za uporabo pri zdravljenju s starostjo povezanih stanj | |
IL264641A (en) | Acetyl-leucine for use in the treatment of neurodegenerative diseases | |
IL266530B1 (en) | Use of Amcol for the treatment of fibrosis | |
IL272027B (en) | Endothelial prodrugs for use in cancer treatment. | |
HUE053927T2 (hu) | Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra | |
HK1257935A1 (zh) | 氨基糖苷衍生物及其在治療遺傳性病症中的應用 | |
PT3197839T (pt) | Método e disposição para tratamento de águas residuais | |
FI3551189T3 (fi) | Alpratsolaami epilepsian hoitoon | |
IL262143A (en) | Improvements in cancer treatment | |
ZA201802618B (en) | Anti-cd43 antibody and use thereof for cancer treatment | |
IL252904A0 (en) | Methods and factors for treating diseases | |
PT3406258T (pt) | Medicamento para utilização no tratamento de gota | |
GB201615844D0 (en) | Agents for use in therapy | |
GB201604658D0 (en) | Treatment for pain | |
GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
HRP20191908T1 (hr) | Paroksizmalni ekstremni bolni poremećaj | |
GB201702652D0 (en) | Delta-theraphotoxin-Ac1 for use in treating diabetes | |
GB201505205D0 (en) | Treatment for pain | |
GB201504688D0 (en) | Treatment for pain |